AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters



AstraZeneca has proposed designs for its new Global R&D center and corporate headquarters in Cambridge, UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the global center, an R&D enabling building, and an energy center.

The new site will bring together AstraZeneca’s small molecule and biologics research and development activity, opening up more opportunities for biologics and small molecule combinations. The CBC will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune currently employs around 500 people at Granta Park, to the southeast of the city.

In advance of the new site to be finished in late 2016, around 70 AstraZeneca staff have already relocated to interim facilities in Cambridge, at the Melbourn Science Park, Cambridge Science Park, and Granta Park. By the end of 2014 approximately 300­–400 AstraZeneca staff will have relocated to the city.

Designs for AstraZeneca’s new site are being made available as part of a public consultation for the local community, ahead of submission of a detailed planning application in autumn 2014. AstraZeneca expects to begin building the new site in early 2015.

Source: AstraZeneca

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here